Cátedra de Enfermedades Infecciosas y
VIH/SIDA
JOURNAL CLUB
Artículos científicos comentados en formato de texto. El comentario incluirá los objetivos/preguntas principales del artículo, los métodos utilizados, los resultados obtenidos y las conclusiones del estudio. El comentario explicará específicamente la validez de los métodos y contextualizará los resultados y sus posibles implicaciones.
- 48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia. Hickey MD, Gistand N, Grochowski J et al. Clinical Infectious Diseases, 20 November 2024
- Comentado por Javier García
- Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations
- Comentado por Miguel García.
-
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis. NEJM
-
Comentado por Enrique Bernal.
- Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
- Comentado por Pere Domingo.
- Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.
- Comentado por Vicente Estrada.
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024
- Comentado por Federico García.
- Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. Paul Thoueillea, Susana Alves Saldanhaa, Fabian Schaller et al. The Lancet.
- Comentado por Miguel Górgolas.
- Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: a modelling study. Sara Bettonte, Mattia Berton, Felix Stader et al. Clinical Infectious Diseases, 03 February 2024
- Comentado por Mar Masiá.